Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

(2021) Henrik Zetterberg et al.   Molecular Neurodegeneration

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neuroinflammation predicts disease progression in progressive supranuclear palsy

(2021) Maura Malpetti et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

(2021) Claudia Cicognola et al.   Alzheimers Research & Therapy

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease

(2021) Cécile Tissot et al.   Alzheimers Research & Therapy

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects

(2021) Joana B Pereira et al.   BRAIN

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias

(2021) Daniel Alcolea et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance

(2021) Kasper Katisko et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

(2021) Nicholas C. Cullen et al.   Nature Communications

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease

(2021) Zhenxu Xiao et al.   Alzheimers Research & Therapy

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

(2020) Carolin Heller et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

(2020) Nicholas J. Ashton et al.   Nature Reviews Neurology

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease

(2020) Maria Angeles Prats‐Sedano et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease

(2020) Sara Hall et al.   MOVEMENT DISORDERS

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

(2019) Patrick Oeckl et al.   JOURNAL OF ALZHEIMERS DISEASE

123I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort

(2019) J.P.M. Kane et al.   PARKINSONISM & RELATED DISORDERS

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

(2019) Claire Bridel et al.   JAMA Neurology

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's disease

(2019) Fanny M. Elahi et al.   Alzheimers & Dementia

Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies

(2018) Paul C. Donaghy et al.   MOVEMENT DISORDERS

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia

(2018) Alan J. Thomas et al.   Alzheimers Research & Therapy

OUP accepted manuscript

(2018)   BRAIN

Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers

(2018) Andrea Vergallo et al.   Alzheimers & Dementia

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

(2017) Günter U. Höglinger et al.   MOVEMENT DISORDERS

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses

(2017) W Richard Bevan-Jones et al.   BMJ Open

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration

(2015) Aiko Ishiki et al.   JOURNAL OF NEUROCHEMISTRY

Neuroinflammation in Lewy body dementia

(2015) Ajenthan Surendranathan et al.   PARKINSONISM & RELATED DISORDERS

The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders

(2013) T. Rittman et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

(2011) Katya Rascovsky et al.   BRAIN

Classification of primary progressive aphasia and its variants

(2011) M. L. Gorno-Tempini et al.   NEUROLOGY